Lamotrigine is More Likely to Provide Benefit Than Buspirone After SSRI/SNRI Failure
When SSRIs and SNRIs have failed, lamotrigine augmentation demonstrates superior evidence for antidepressant effects compared to buspirone, which has shown inconsistent and weak results in treatment-resistant depression.
Evidence for Lamotrigine Augmentation
Lamotrigine has demonstrated meaningful antidepressant properties when added to existing antidepressant therapy, particularly in treatment-resistant cases:
Accelerated onset of action: Lamotrigine augmentation of SSRIs showed significant efficacy on core depressive symptoms including depressed mood (p=0.0019), guilt feelings (p=0.0011), and work/interest (p=0.049), with faster clinical improvement compared to standard treatment 1
Treatment-resistant depression: In a comparative study of 88 patients with treatment-resistant major depression, lamotrigine augmentation (50-200 mg/day) achieved significant clinical improvement within the second treatment week, with lower treatment failure rates (n=1) compared to lithium augmentation (n=4) 2
Mechanism: Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic release of excitatory amino acids (glutamate, aspartate), providing a distinct mechanism from SSRIs/SNRIs 3
Safety profile: Mood stabilizers including lamotrigine have generally not been associated with severe cardiac arrhythmias, unlike SSRIs which carry increased cardiac arrest risk (OR=1.21) 4
Evidence Against Buspirone Augmentation
Buspirone has consistently failed to demonstrate superiority over placebo in rigorous studies:
Placebo-controlled failure: The largest randomized, double-blind, placebo-controlled trial (N=119) found no statistically significant difference between buspirone augmentation (50.9% response) and placebo augmentation (46.7% response) of SSRIs after 4 weeks 5
Weak effects in severe depression: A naturalistic study of 10 inpatients with refractory severe depression showed only 2 cases of partial remission and 5 cases of minimal improvement with 30 mg buspirone augmentation—no complete recoveries 6
Inconsistent results: While one retrospective chart review reported 43% response rates 7, this was uncontrolled and contradicted by the subsequent placebo-controlled trial 5
Clinical Implementation Algorithm
Start lamotrigine augmentation using this titration schedule:
- Week 1-2: 25 mg daily
- Week 3-4: 50 mg daily
- Week 5-6: 100 mg daily
- Week 7+: Target 100-200 mg daily based on response
Monitor for:
- Clinical improvement in depressed mood, guilt, and functional capacity within 2 weeks 2
- Serious rash (discontinue immediately if occurs)
- Neutropenia (rare but reported) 1
Avoid buspirone given the high placebo response rate (46.7%) and lack of demonstrated efficacy over placebo in controlled trials 5
Critical Caveats
Cardiac considerations: While lamotrigine exhibits Class IB antiarrhythmic activity in vitro, patients with structural heart disease, heart failure, conduction abnormalities, or cardiac channelopathies may experience ventricular conduction slowing and proarrhythmia 3. Screen with ECG if cardiac risk factors present.
Buspirone contraindications: Buspirone is contraindicated with MAOIs and carries risk of serotonin syndrome when combined with other serotonergic agents 8. However, this is largely irrelevant given its lack of efficacy.
Diagnostic clarity: Lamotrigine is FDA-approved for bipolar disorder maintenance 9, so if diagnostic uncertainty exists between unipolar and bipolar depression, lamotrigine offers coverage for both conditions while buspirone does not.
The evidence strongly favors lamotrigine over buspirone for augmentation after SSRI/SNRI failure, with lamotrigine showing consistent benefits on core depressive symptoms and faster onset of action 1, 2, while buspirone failed to separate from placebo in the definitive controlled trial 5.